A Phase 3 interventional study of Mesenchymal Stem Cells and Sodium Hyaluronate Injection in Knee Osteoarthritis, sponsored by Wuxi Cellular Biopharmaceutical Group Ltd.. Recruiting at 2 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by Wuxi Cellular Biopharmaceutical Group Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.
Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 7th largest by planned enrollment of the 115 interventional ones that give a count, is one of 10 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 18 of the 31 other live ones, and was the 107th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
China-Japan Friendship Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 18–65
Belief BioMed (Beijing) Co., Ltd · Sites in China
Ages 40–75
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 40–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 15 · Phase 4 15
First in 2000; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 520 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 100 across the 115 interventional studies, 136 across the 21 observational. Of the 53 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 136 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Wuxi Cellular Biopharmaceutical Group Ltd. as lead sponsor.
Wuxi Cellular Biopharmaceutical Group Ltd. has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
10 of the studies in Osteoarthritis, Knee with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06570291Phase 3Wuxi Cellular Biopharmaceutical Group Ltd.Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis | 2026-12 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07504562ShuGuang HospitalKnee Pain Ejiao Paste for Knee Osteoarthritis | 2026-12-31 |
| NCT03383081Sclnow Biotechnology Co., Ltd.The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis | 2026-12-31 |
| NCT06010979Tian HuaClinical Cohort Study of Knee Arthroplasty Assisted by Digital Technology | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 136 studies in Osteoarthritis, Knee with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mesenchymal Stem Cells
Drug: Sodium Hyaluronate Injection
Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use
Sodium Hyaluronate administrated for intra-articular use
WOMAC score
The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points;96 points mean a worse outcome,will be tested at 48 weeks after the first injection
Time frame: 48 weeks
MRI quantitative analysis of articular cartilage
Time frame: 24 weeks
WOMAC Score
The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points;96 points mean a worse outcome, will be tested at 4、12、24、36、60、72、84 and 104 weeks after the first injection
Time frame: 4、12、24、36、60、72、84 and 104 weeks
MRI quantitative analysis of articular cartilage (volume change percentage)
Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 12、48、104 weeks after the first injection
Time frame: 12、48、104 weeks
MRI quantitative analysis of articular cartilage (volume change)
Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 12、24、 48 and 104 weeks after the first injection
Time frame: 12、24、 48 and 104 weeks
VAS Score
Visual Analogue Scale/Score;0-10 points;10 points mean the worse outcome,will be tested at 4、12、24、36、48、60、72、84 and 104 weeks after the first injection
Time frame: 4、12、24、36、48、60、72、84、104 weeks
SF-36
The Medical Outcomes Study 36-Item Short-Form Health Survey;0-100 points;100 points mean a better outcome, will be tested at 4、12、24、36、48、60、72、84 and 104 weeks after the first injection
Time frame: 4、12、24、36、48、60、72、84、104 weeks
Whole-Organ Magnetic Resonance Imaging Score
Whole-Organ Magnetic Resonance Imaging Score(WORMS) of the knee; 0-332points; 332 points means the worst outcome; will be assessed at 12、24、48 and104 weeks
Time frame: 12、24、48 and 104 weeks
mJSW
Minimum joint space width (mJSW) of the knee, will be measured at baseline and 104 weeks
Time frame: 104 weeks
Physical examination
Height and weight will be tested and combined to report BMI in kg/m\^2at Day 0 and week 1、2、3、4、12、24、36、48、60、72、84、104 weeks
Time frame: Day 0、week 1、2、3、4、12、24、36、48、60、72、84、104 weeks
Adverse Events and Serious Adverse Events
AE and SAE, will be assessed within the 104 week time span
Time frame: Day 0 to 104 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 22 months is close to that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.